2 results
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOPending
The primary hypothesis of the study is that the use of icodextrin leads to a reduction in extracellular volume compared to glucose 2.27%, but that the effects of icodextrin and glucose 2.27% on plasma will not differ.